PA-BENTLEY-SYSTEMS
13.4.2022 22:03:02 CEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced its call for nominations for the 2022 Going Digital Awards in Infrastructure . This juried awards program celebrates the most exemplary projects that represent going digital advancements in infrastructure. The deadline for nominations is May 23, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005989/en/
The Going Digital Awards in Infrastructure categories include:
- Bridges and Tunnels
- Construction
- Enterprise Engineering
- Facilities, Campuses, and Cities
- Geoprofessional
- Grid
- Process and Power Generation
- Rail and Transit
- Roads and Highways
- Structural Engineering
- Surveying and Monitoring
- Water and Wastewater
The categories for the 2022 Going Digital Awards in Infrastructure encompass all forms of infrastructure projects and stages—from design, to construction, to operations. Since 2004, the Going Digital Awards in Infrastructure program has recognized more than 4,400 of the world’s most outstanding infrastructure projects. Open to all Bentley software users, it is a unique program that is global in scope, with entries typically representing more than 40 countries.
These projects recognize innovative advancements and measurable impacts in infrastructure and sustainability. Projects may be recognized for their economic impact and innovative use of Bentley software, including the Bentley iTwin platform and infrastructure digital twins, 4D modeling, Infrastructure Internet of Things, and artificial intelligence. Projects may also be recognized for advancements that empower sustainable development goals in terms of climate action, energy transition and efficiency, circularity of land and water resources, and healthy communities.
Users are invited to nominate their projects for the Going Digital Awards in Infrastructure program, no matter which phase their project is in—planning/conception, design, construction, or operations. The Going Digital Awards finalists in each category will be recognized at an awards celebration in London in Q4 2022. This exclusive gathering provides an opportunity for awards finalists to present their going digital advancements to an audience of press, analysts, and infrastructure executives.
In addition to the juried awards, Bentley’s Founders will honor projects that transcend the narrower focus of the individual category awards, either through uniquely innovative use of Bentley software or by empowering sustainable development goals.
Every project nominated for an award receives recognition across the global infrastructure community. Through the Going Digital Awards in Infrastructure program participants:
- Get their infrastructure projects profiled in Bentley’s Infrastructure Yearbook , which is distributed in print and digital formats to media, government, and industry influencers around the world.
- Enhance their competitive edge by demonstrating to existing and potential clients the value the participants add to projects through their digital innovations.
- Receive coverage from global media and support from the Bentley team in marketing and promoting their respective projects to the media.
For additional information about the 2022 Going Digital Awards in Infrastructure program, or to nominate a project, visit the Going Digital Awards in Infrastructure website.
Watch this video to discover why you should nominate your project for Going Digital Awards in Infrastructure .
##
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geoprofessional software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,500 colleagues and generates annual revenues of approximately $1 billion in 186 countries.
© 2022 Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005989/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom